GEOVAX LABS INC (GOVX) Stock Overview
USA - NASDAQ:GOVX - US3736786068 - Common Stock
GOVX Key Statistics, Chart & Performance
The current stock price of GOVX is 0.5749 USD. In the past month the price decreased by -17.51%. In the past year, price decreased by -71.68%.
GOVX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.74 | 406.64B | ||
| AMGN | AMGEN INC | 13.49 | 158.34B | ||
| GILD | GILEAD SCIENCES INC | 14.67 | 140.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.78 | 103.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 85 | 48.22B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.56 | 37.84B | ||
| INSM | INSMED INC | N/A | 33.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 23.38B | ||
| BIIB | BIOGEN INC | 9.62 | 22.59B |
Related stock screener links
About GOVX
Company Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
Company Info
GEOVAX LABS INC
1900 Lake Park Drive, Suite 380
Smyrna GEORGIA 30080 US
CEO: David A. Dodd
Employees: 17
Phone: 16783847220
GEOVAX LABS INC / GOVX FAQ
What is the stock price of GEOVAX LABS INC today?
The current stock price of GOVX is 0.5749 USD. The price decreased by -0.86% in the last trading session.
What is the ticker symbol for GEOVAX LABS INC stock?
The exchange symbol of GEOVAX LABS INC is GOVX and it is listed on the Nasdaq exchange.
On which exchange is GOVX stock listed?
GOVX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GEOVAX LABS INC stock?
11 analysts have analysed GOVX and the average price target is 10.1 USD. This implies a price increase of 1656.48% is expected in the next year compared to the current price of 0.5749. Check the GEOVAX LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GEOVAX LABS INC worth?
GEOVAX LABS INC (GOVX) has a market capitalization of 14.58M USD. This makes GOVX a Nano Cap stock.
How many employees does GEOVAX LABS INC have?
GEOVAX LABS INC (GOVX) currently has 17 employees.
What are the support and resistance levels for GEOVAX LABS INC (GOVX) stock?
GEOVAX LABS INC (GOVX) has a support level at 0.48 and a resistance level at 0.66. Check the full technical report for a detailed analysis of GOVX support and resistance levels.
Is GEOVAX LABS INC (GOVX) expected to grow?
The Revenue of GEOVAX LABS INC (GOVX) is expected to decline by -56.94% in the next year. Check the estimates tab for more information on the GOVX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GEOVAX LABS INC (GOVX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GOVX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GOVX, evaluating the profitability, health, valuation and growth aspects
- GEOVAX LABS INC (GOVX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GEOVAX LABS INC (GOVX) Sales and EPS estimates to see what analysts future expectations are.
- GEOVAX LABS INC (GOVX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GEOVAX LABS INC (GOVX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GEOVAX LABS INC (GOVX) Stock Chart to make your own analysis
- GEOVAX LABS INC (GOVX) Latest news and press-releases to stay up to date.
Does GEOVAX LABS INC (GOVX) stock pay dividends?
GOVX does not pay a dividend.
When does GEOVAX LABS INC (GOVX) report earnings?
GEOVAX LABS INC (GOVX) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of GEOVAX LABS INC (GOVX)?
GEOVAX LABS INC (GOVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).
What is the Short Interest ratio of GEOVAX LABS INC (GOVX) stock?
The outstanding short interest for GEOVAX LABS INC (GOVX) is 15.94% of its float. Check the ownership tab for more information on the GOVX short interest.
GOVX Technical Analysis
GOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GOVX. GOVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GOVX Financial Highlights
Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS increased by 91.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -463.62% | ||
| ROE | -879.26% | ||
| Debt/Equity | 0 |
GOVX Forecast & Estimates
11 analysts have analysed GOVX and the average price target is 10.1 USD. This implies a price increase of 1656.48% is expected in the next year compared to the current price of 0.5749.
For the next year, analysts expect an EPS growth of 76.85% and a revenue growth -56.94% for GOVX